RenovaCare (OTC:RCAR) Stock, Quote.Headers.trade-ideas

RenovaCare Inc is a biotechnology company focusing on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The company's initial products under development target skin. It offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). RenovaCare is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Geographically all the activities are functioned through the region of United States.

finance money crime shutter

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

News

Health Care

Markets

General

RCAR

Army swindler sets up children&#39;s charity to commit fraud and investment scammers use &#39;SkinGun&#39; product to dupe investors.

Bitcoin Laundering, &#39;Gucci Goddess&#39; Army Swindle And Healthcare &#39;Pump And Dump&#39; Scam: Financial Crime Weekly

Intraday Update

Movers

Trading Ideas

AACAF

AACAY

AAPL

ACLS

AFGC

AGPPF

AHAG

AINV

AIQUY

ALFVY

AMCI

AMGN

AMTBB

ANGPY

APAM

APRE

APTO

AQUA

ARES

ARLUF

ARNC

AROW

ARVN

ASGN

ASML

ASMVY

ATLKF

ATLKY

ATVI

AUCOY

AUPH

AVGO

BABA

BANF

BLDR

BNPQY

BNTX

BPIGF

BPXXY

BRBOF

BRK-A

BRK-B

BRKL

CALB

CARE

CARO

CBRE

CBSH

CDMO

CGECF

CGGYY

CHDN

CMRE

CNOB

CPXWF

CRAI

CRARY

CRHCF

CRUS

CSTM

CTBI

CTXXF

Stocks That Hit 52-Week Highs On Thursday

Movers & Shakers

AAVXF

ACLLF

AHCHY

AIMT

ALCO

ALLE

ARCAY

ARGX

ASPU

ASUUY

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

BOCH

BOLD

BUKS

CCLAF

CRSS

CUBA

DCPH

DEWY

DFCO

DPMLF

EDTXF

EFIN

EGRN

ENIA

ERRFY

ESLT

FELE

FLXN

FORM

FORTY

FSUGY

FTSV

GLDD

GOLF

GOSS

GSBD

GSGTF

HBAN

ICBK

IDEXF

IDEXY

IMKTA

IMMU

IMPUF

IMPUY

INCY

INSG

ISEE

ITOCF

IVSXF

JADSF

JPRRF

KKKUF

KRMD

Stocks That Hit 52-Week Highs On Wednesday

RenovaCare Inc

<a href="https://www.bloomberg.com/news/articles/2024-09-25/olympics-caterer-sodexo-is-said-to-weigh-acquisition-of-aramark?embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2024-09-25/olympics-caterer-sodexo-is-said-to-weigh-acquisition-of-aramark?embedded-checkout=true">https://www.bloomberg.com/news/articles/2024-09-25/olympics-caterer-sodexo-is-said-to-weigh-acquisition-of-aramark?embedded-checkout=true</a>

ARMK

SDXAY

Bloomberg Reported Sodexo Weighs Acquisition Of Aramark

Billionaire Chamath Palihapitiya shared his thoughts on immigration and how the media portrays Donald Trump during a sit-down interview with Joe Rogan, who remains one of the <a href="https://www.benzinga.com/general/entertainment/23/11/36004998/joe-rogan-tops-spotifys-2023-podcasts-list-once-again-deal-likely-to-expire-in-2024-a-major">most popular podcasters.</a>
Chamath On Immigration: The topic of immigration is one of the top voter issues in <a href="https://www.benzinga.com/topic/2024-election">the 2024 election </a>and Palihapitiya believes whoever wins the election will have to act on the crisis.
"Both of them will probably have to act," Palihapitiya <a href="https://www.youtube.com/watch?v=we-mZ-KTe-8">said</a> on episode #2206 of &#8220;The Joe Rogan Experience.&#8221; 
Palihapitiya said he likes to give both candidates the benefit of the doubt on the issue, despite Rogan criticizing the current Biden administration, which includes Vice President Kamala Harris, not doing enough.
"I think that Donald Trump has had a clearer view of this issue for much far longer. I think that Kamala has had to shift her position."
The billionaire investor said the two political sides likely differ about how to handle immigration and foreign policy.
Rogan said there are pros and cons of immigration, citing the need for cheap labor. The podcast host questions if there is an incentivized effort to bring people into the country illegally and buying the vote, as he says Elon Musk has alleged.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent092524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Chamath on Media: When it comes to how Donald Trump is portrayed by the media, Palihapitiya said the media lies about him, including a comment about "very fine people" said during a speech in Charlottesville.
"I met him and spent time with him," Palihapitiya said of Trump.
The billionaire investor said Trump was kind and "he talks to you," which he wasn't expecting due to the media's portrayal of the former president.
"I think the media really gets tilted."
Rogan said Trump&#8217;s flaws are nothing compared to how the media depicts him, which Palihapitiya agreed with and said Trump's flaws are well described already.
The media's depiction of Trump could have a negative impact, the investor added.
"The trust in the mainstream media is the lowest it has ever been."
Palihapitiya said he's also had "lunch with Kamala" and said she was very kind and a "very nice person."
Musk <a href="https://x.com/elonmusk/status/1839043088833995194">shared </a>a clip on Palihapitiya and Rogan discussing the media's depiction of Trump and said that they had "good points."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40306405/after-trump-slams-joe-rogan-for-rfk-jr-endorsement-podcast-host-walks-back-remarks-saying-im-not-the">After Trump Slams Joe Rogan For RFK Jr Endorsement, Podcast Host Walks Back Remarks, Saying &#8216;I&#8217;m Not The Guy To Get Political Information From&#8217;</a></li>
</ul>
Photo: Featureflash Photo Agency on Shutterstock

Entertainment

Politics

Media

Chamath Palihapitiya Tells Joe Rogan That Trump, Harris Have To Act On The Border: 'I Think That Donald Trump Has Had A Clearer View Of This Issue'

Toria Lyttle, a 43-year-old mother from Newtownards, in Northern Ireland, turned to medical marijuana to manage her severe migraines, which have plagued her since <a href="https://www.benzinga.com/markets/cannabis/23/12/36228666/the-kids-are-alright-government-study-finds-teen-cannabis-use-holds-steady-despite-increased-sta">childhood. </a>
With monthly prescription costs reaching up to 350 pounds sterling ($366), Toria's case underscores the ongoing challenges of accessing alternative treatments for chronic pain in the UK, <a href="https://www.wfxg.com/news/health-news-now/mom-says-cannabis-cured-migraines-she-s-had-for-30-years/article_507b97f9-28a9-5d62-8377-7cff579f533a.html">reported</a> Fox 54 News.
See Also: <a href="https://www.benzinga.com/markets/cannabis/23/04/31728661/can-marijuana-help-with-migraines-ms-related-chronic-pain-new-clinical-guidelines-are-here">Can Marijuana Help With Migraines? MS-Related Chronic Pain? New Clinical Guidelines Are Here</a>
<h3 class="wp-block-heading">Living With Chronic Migraines</h3>
Toria has battled migraines since she was nine. The situation became worse when doctors diagnosed her with a benign brain tumor three years ago.
Despite the diagnosis, her migraines persisted, leading to years of disrupted sleep, pain and an inability to live her life fully. "I've lived with these awful migraines my whole life, but no one could ever tell me why I suffered with them," Toria said.
Before turning to medical cannabis, she had been prescribed various painkillers, none of which eased her symptoms, often making her feel worse. Desperate for a solution, Toria approached her doctor in September 2023 about trying medical marijuana.
<h3 class="wp-block-heading">Turning To Medical Cannabis</h3>
After consulting with a specialist at the private medical cannabis clinic Alternaleaf, Toria received a prescription for 30 grams of THC-containing cannabis each month. She now vapes two to four doses daily, depending on the severity of her symptoms. She says the change has been transformative.
"Medicinal cannabis has allowed me to live again," she said. "It has lightened my world because I don't feel terrified about the next migraine anymore and it's much fairer for the people around me, too, because my temper is so much better."
Though the cannabis has not eliminated her pain entirely, it has significantly improved her condition, allowing her to sleep through the night and function during the day. 
"It hasn't taken the pain away completely, but I can manage it now," she added.
<h3 class="wp-block-heading">Cannabis Study Confirms Efficacy For Migraine Sufferers</h3>
Meanwhile, research presented at the 2023 American Headache Society Annual Meeting validates the effectiveness of cannabis for migraines, echoing the life-changing relief experienced by Lyttle. 
The <a href="https://www.benzinga.com/markets/cannabis/23/06/32914574/vaporized-cannabis-a-promising-migraine-treatment-suggests-study-at-american-headache-society-me">study</a>, led by Dr. Nathaniel Schuster, found that a combination of THC and CBD significantly reduced migraine symptoms within two hours of use.
Patients were randomly assigned to either tetrahydrocannabinol (THC) 6%, a mix of THC and cannabinoid (CBD) 11%, CBD 11% and placebo cannabis.
&#8220;The doses that we used are probably lower than what a lot of people out there are using on their own, and higher doses do not necessarily mean more effective,&#8221; Schuster said. &#8220;The highness patients were having in the study was not very high, probably somewhere between a 2-4 out of 10 on subjective highness."
Migraines&nbsp;affect&nbsp;47 million Americans,&nbsp;75%&nbsp;of whom are women. Although a splitting&nbsp;headache is one symptom, migraine attacks can include visual disturbances, nausea, extreme light and sound sensitivity, brain fog and debilitating pain.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39843370/tevas-migraine-treatment-found-effective-for-children-as-young-as-6">Teva&#8217;s Migraine Treatment Found Effective For Children As Young As 6</a></li>
</ul>
Cover image made with AI.

Cannabis

Chronic Migraines And Cannabis: How One Mom Found Relief After A Lifetime Of Pain

Florida Gov. <a href="https://www.benzinga.com/topic/ron-desantis">Ron DeSantis</a> (R) faces a public relations lashing for leveraging a taxpayer-funded advertisement to influence voters against the marijuana legalization measure, known as <a href="https://www.benzinga.com/markets/cannabis/24/04/38034138/florida-supreme-court-approves-cannabis-legalization-proposal-for-november-election-in-blow-to-d">Amendment 3</a>, which will be decided upon in the <a href="https://www.benzinga.com/topic/2024-election">November 2024 election</a>. 
The ad, produced by the Florida Department of Transportation, warns against the dangers of driving under the influence of cannabis.
In the middle of the 30-second video warning viewers not to drive high, the narrator says, "DUI crashes increase in states with legalized marijuana, putting everyone at risk."
<h1 class="wp-block-heading">Outrage Ensues</h1>
The ad sparked anger among advocates with Smart &amp; Safe Florida, the campaign that helped put Amendment 3 on the ballot. The campaign called the DeSantis-backed Vote No on 3 political committee of using state resources to amplify an opposition talking point at a lower cost by channeling the message through a government agency.
The campaign sent cease and desist letters to about 50 news stations across Florida. In it, the group condemns the use of taxpayer money to disseminate what they call a "ruse to obtain the highly discounted rates" for airing PSAs.
"Florida law demands that campaigns be operated in the sunshine," the Smart &amp; Safe letter said. "Accepting taxpayer funds to broadcast State Propaganda under the guise of a public service announcement — and at an anticompetitive and severely discounted rate — should not be countenanced."
The campaign also criticized the refusal of TV stations to air what Smart &amp; Safe called a &#8220;politically neutral&#8221; alternative, accusing them of participating in a scheme to secure discounted rates for the ad. The news was&nbsp;<a href="https://subscriber.politicopro.com/article/2024/09/florida-pot-legalization-psa-00180788?source=email" target="_blank" rel="noreferrer noopener">first reported by Politico</a>&nbsp;on Tuesday.
Suggesting a direct link between marijuana legalization and increased impaired driving is seen as misleading, with some research indicating mixed results on the matter. Federal reports have also stated that the impact of cannabis on driving is not yet fully understood.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/41016011/florida-cannabis-ballot-nfls-ricky-williams-backs-legalization-new-ad-hypocrisy-of-alcohol-vs-ma">Florida Cannabis Ballot: NFL&#8217;s Ricky Williams Backs Legalization, New Ad &#8216;Hypocrisy Of Alcohol Vs. Marijuana&#8217;</a>
<h1 class="wp-block-heading">GOP and Dem Politicians Weigh In</h1>
The controversy has drawn further attention from political figures like <a href="https://www.benzinga.com/topic/nikki-fried">Nikki Fried,</a> chair of the Florida Democratic Party, who criticized DeSantis for using public funds to campaign against not only the marijuana legalization initiative but a separate reproductive rights measure, known as Amendment 4.
Meanwhile, <a href="https://www.benzinga.com/markets/cannabis/24/09/40969689/desantis-urges-gop-to-oppose-cannabis-legalization-as-party-splits-over-trump-marijuana-endorsem">Jeff Brandes</a>, a former Republican state senator, warned that the governor&#8217;s actions set a dangerous precedent, suggesting that such use of public funds may not be permissible under Florida&#8217;s budget.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40969689/desantis-urges-gop-to-oppose-cannabis-legalization-as-party-splits-over-trump-marijuana-endorsem">DeSantis Urges GOP To Oppose Cannabis Legalization As Party Splits Over Trump Marijuana Endorsement</a></li>
</ul>
Photo: Benzinga&nbsp;edit of image by&nbsp;<a href="https://unsplash.com/fr/@mrbrodeur?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText" target="_blank" rel="noreferrer noopener">Matthew Brodeur</a>&nbsp;on&nbsp;<a href="https://unsplash.com/photos/qcCPIhhdgTw?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText" target="_blank" rel="noreferrer noopener">Unsplash</a>&nbsp;and Wikimedia Commons

Regulations

DeSantis Provokes Outrage Over Taxpayer-Funded Ads Linking Marijuana Legalization To Car Crashes

Sales of single-family homes fell last <a href="https://www.benzinga.com/real-estate/24/06/39465243/u-s-home-sales-decline-for-third-month-as-record-prices-pose-persistent-affordability-challenges-dur">month from July </a>but rose from a year ago as mortgage rates kept falling.
New single-family home sales fell 4.7% in August from the prior month to an annualized rate of 716,000, according to estimates released on Wednesday by the U.S. Census Bureau and the Department of Housing and Urban Development.
That was up 9.8% from an annualized rate of 652,000 home sales in August 2023.
The latest month-over-month decline was in contrast to a 10.3% jump in single-family home sales from June to July.
Single-family home sales fell the most from July to August in the West, falling 17.8% to an annualized rate of 152,000 in that region.
Read Also: <a href="https://www.benzinga.com/real-estate/24/06/39398524/home-sales-suffer-third-worst-month-in-the-last-10-years">Home Sales Suffer Third Worst Month In The Last 10 Years</a>
Sales of all homes, which also included condominiums, townhomes and co-ops, slipped 2.5% from July to a seasonally adjusted annual rate of 3.86 million in August, according to latest figures from the National Association of Realtors (NAR). Year-over-year sales for August declined 4.2% from 4.03 million in August 2023.
"Home sales were disappointing again in August, but the recent development of lower mortgage rates coupled with increasing inventory is a powerful combination that will provide the environment for sales to move higher in future months," NAR chief economist Lawrence Yun said.
"The home-buying process, from the initial search to getting the house keys, typically takes several months."
The interest rate on a 30-year mortgage fell to a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41024067/mortgage-demand-soars-as-fed-interest-rate-cut-fuels-housing-market-revival-next-sp">two-year low of 6.13%</a>, a week after the Federal Reserve cut interest rates by 50 basis points to mark the first Fed rate cut in four years.
Price Action: Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>), one of the largest homebuilders with a market cap of $49.5 billion, slipped 1.29% to close Wednesday at $181.86.
<ul>
<li>IShares U.S. Home Construction ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITB#BATS">ITB</a>) slipped 1.71%</li>
<li>Direxion Daily Homebuilders &amp; Supplies Bull 3X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NAIL#NYSE">NAIL</a>) fell 4.94%</li>
<li>AdvisorShares Gerber Kawasaki ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GK#NYSE">GK</a>) went up 0.17%</li>
</ul>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/07/39909262/us-home-sales-see-sharpest-monthly-decline-in-1-5-years-as-record-high-prices-keep-buyers-on-the-s">US Home Sales See Sharpest Monthly Decline In 1.5 Years As Record High Prices Keep Buyers On The Sideline</a></li>
</ul>
Photo: Floridastock via Shutterstock

REIT

iShares Dow Jones US Homenstruction Index Fund

NAIL

New US Single-Family Home Sales Fall From Prior Month — But Are Up From A Year Ago As Mortgage Rates Decline

BofA Securities says U.S. consumers are focused on value and sees Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) well-positioned in the e-commerce industry to reap the benefits heading <a href="https://www.benzinga.com/news/24/09/41023224/top-10-stock-picks-for-the-holiday-boom-adobe-forecasts-unprecedented-e-commerce-sales-this-season">into the holiday season.</a> 
What To Know: On Wednesday, BofA released its 2025 annual e-commerce survey which monitors sector trends, inflections and outlook for the next year. The research firm expects e-commerce to grow its market share during the upcoming holiday season as consumers are drawn to online shopping by convenience, price comparability and a shorter holiday shopping window after Thanksgiving.&nbsp;
The survey revealed 52% of respondents expect to increase their online spending year-over-year, compared to 46% last year. However, 62% of respondents said they are seeking lower prices due to economic changes and uncertainty about the upcoming Presidential election. 
Read Next:<a href="https://www.benzinga.com/news/24/09/41011763/whats-going-on-with-intel-stock"> What&#8217;s Going On With Intel Stock?</a>
Why It Matters: BofA sees retailers offering consumables and value pricing, such as Walmart and Amazon, as best-positioned to gain market share as consumers look for lower prices and price comparability in an uncertain environment. 
Walmart remained the most popular online grocery retailer with 30% of respondents opting for the grocery giant. Amazon saw the highest spending intentions in the survey, with 45% of respondents intending to increase their usage over the next six months.&nbsp;
Sixty-seven percent of respondents reported using Temu, a subsidiary of PDD Holdings, Inc. &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), a gain of 13 points year-over-year. However, only 20% intend to increase their Temu usage, down by eight points from last year. 
Overall, BofA forecasts healthy consumer online spending in the upcoming holiday shopping season with a shift from discretionary categories into consumables.&nbsp;
AMZN, WMT, PDD Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Amazon shares closed Wednesday's session down 0.74% at $192.53, Walmart shares rose 0.90% to $81.40 and PDD Holdings shares ended the session 0.12% higher at $113.94. 
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40991529/what-happened-with-palantir-stock-today">What Happened With Palantir Stock Today?</a></li>
</ul>
Photo: Jill Wellington from Pixabay

Analyst Color

AMZN

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Expect Healthy Online Spending This Holiday Season, Says Analyst: What To Know

Investcorp Credit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICMB#NASDAQ">ICMB</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.13 by 30.77 percent.

Earnings

Earnings Misses

ICMB

Investcorp Credit Q4 2024 GAAP EPS $0.09 Misses $0.13 Estimate

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is one of several companies benefitting from demand for weight loss drugs. The company is also seeing competition in the market including knockoff drugs that it said <a href="https://www.benzinga.com/general/biotech/24/08/40376247/dont-promote-copycat-weight-loss-drugs-amid-improved-supply-eli-lilly-asks-doctors-fda-evaluates">could be unsafe</a>.
What Happened: A recent report says Eli Lilly is seeking medical records of people who took knockoff <a href="https://www.benzinga.com/topic/weight-loss">weight loss drugs.</a>
The request, reported by <a href="https://www.bloomberg.com/news/articles/2024-09-19/lilly-wants-records-from-people-who-took-weight-loss-knockoffs?sref=TBDibEcD">Bloomberg</a>, is being done for safety reasons according to the pharmaceutical company.
Eli Lilly is building a case against businesses that are selling knockoffs of the company's Zepbound and Monjaro. Compounding pharmacies have been capitalizing on Lilly seeing supply constraints and shortages while demand remains high.
Lilly has said that the quality of the compounding pharmacies products are inferior and questions the safety profile of the treatment.
A letter viewed by Bloomberg requested information from a patient who took a Lilly product from a compounded pharmacy.
"We would appreciate if you could complete the enclosed form and sign the Authorization for Release of Medical Information so that we can obtain more details from the treating physician around your experience," the letter says.
Along with items like the letter, Eli Lilly also took out an advertisement in national publications encouraging patients to make sure they are taking the "real product."
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/09/41033009/can-novo-nordisks-weight-loss-drug-ozempic-help-stem-the-devastating-addiction-crisis-new-resear"> Can Novo Nordisk&#8217;s Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes</a>
Why It's Important: Obtaining medical records could be a key in Eli Lilly's battle against compounding pharmacies. The short supply of Lilly and other companies' weight loss drugs helped the argument for a legal loophole that allows compounding of drugs when a supply constraint happens.
If Eli Lilly can prove that the drugs are not as safe and are causing side effects or harm to patients, it could help put a stop to compounding pharmacies. Without proof, Eli Lilly may fall victim to the legal loophole and the issue of soaring demand for its own products.
Eli Lilly <a href="https://www.benzinga.com/general/biotech/24/08/40251130/mounjaro-maker-eli-lillys-bumper-q2-earnings-exceeds-estimates-hikes-outlook-again-on-strong-diab">reported second-quarter </a>revenue of $11.3 billion, up 36% year-over-year. Mounjaro and Zepbound had revenue of $3.1 billion and $1.2 billion, respectively, seeing significant gains in the quarter.
The pharmaceutical company increased its full-year guidance as a result of the second-quarter results and increasing demand for several products.
LLY Price Action: Eli Lilly stock closed Wednesday at $924.56 versus a 52-week trading range of $516.57 to $972.53. Eli Lilly stock is up 56% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41002452/eli-lillys-early-alzheimers-treatment-donanemab-scores-japanese-approval-its-second-largest-marke">Eli Lilly&#8217;s Early Alzheimer&#8217;s Treatment Donanemab Scores Japanese Approval, Its Second Largest Market</a></li>
</ul>
Photo: Shutterstock

Biotech

Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments

Some experts believe Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) products not only help people lose weight and control diabetes, they can help treat the <a href="https://www.benzinga.com/markets/cannabis/24/09/41033009/can-novo-nordisks-weight-loss-drug-ozempic-help-stem-the-devastating-addiction-crisis-new-resear">country&#8217;s addiction crisis.</a> 
The Novo Nordisk chart illustrates two common technical analysis dynamics that <a href="https://www.benzinga.com/quote/NVO">successful traders can use to profit.</a>
As you can see, the $123 level was support for the stock in April. Then it was support again in early August. And after a recent move higher and a reversal, the stock found support around the same level again.
Support can stay intact for an extended time because of investor and trader psychology. It is because there are traders who sold while the stock was at support. But right after they were done selling, the shares rallied.
When this happened, many of these sellers came to regret their decision to get rid of their shares. Some of them decided to buy their shares back. But, they will only do so if they can buy the shares for the same price they were sold.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="979" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25173834/1-26.png" alt="" class="wp-image-566523" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25173834/1-26.png 979w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25173834/1-26-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/25173834/1-26-768x473.png 768w" sizes="(max-width: 979px) 100vw, 979px" /></figure>
Read Also:<a href="https://www.benzinga.com/general/biotech/24/09/41034046/popular-ozempic-may-have-new-use-as-semaglutide-drugs-linked-to-reduced-overdose-risk-in-diabetic"> Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users</a>
So, when the stock reversed and eventually returned to the support level, these remorseful sellers placed buy orders. And there were so many of these buy orders that it created support at the level which had been support before.
Seller's remorse&nbsp;can make support levels stay intact for an extended period of time.
When a stock drops to a support level, there is a tendency for them to reverse and rally. This is also because of psychology. It happens because some of the buyers experience anxiety.
These buyers are worried they will miss the trade. They know that the sellers will go to whoever is willing to pay the highest price.
As a result, they increase the prices they are willing to pay. Other anxious buyers see this and do the same thing.
This results in a bidding war that pushes the price higher.
If understood and interpreted correctly, technical analysis is the study of investor and trader psychology. Seller's remorse can cause support levels to stay intact for an extended period of time. Buyer's anxiety can make stocks rally after the drop to support levels.
Read Next: • <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41028913/bristol-myers-2seventy-bio-halt-phase-3-trial-for-abecma-in-newly-diagnosed-myeloma">Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability</a>
Photo: Shuttersotck

Technicals

Lose Weight With Novo Nordisk Drugs, Gain Money With Stock

Offerings

ASNS

Actelis Networks Entered Into At Market Offering Agreement; May Issue, Sell Shares Of Common Stock Of Up To $3.4M From Time To Time

UBS Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) has outperformed the market over the past 5 years by 7.69% on an annualized basis producing an average annual return of 21.91%. Currently, UBS Gr has a market capitalization of $96.19 billion. 
Buying $100 In UBS: If an investor had bought $100 of UBS stock 5 years ago, it would be worth $265.25 today based on a price of $30.00 for UBS at the time of writing.
<h3>UBS Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727299820_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today

TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) has outperformed the market over the past 15 years by 6.53% on an annualized basis producing an average annual return of 18.56%. Currently, TJX Companies has a market capitalization of $133.24 billion. 
Buying $100 In TJX: If an investor had bought $100 of TJX stock 15 years ago, it would be worth $1,271.92 today based on a price of $118.13 for TJX at the time of writing.
<h3>TJX Companies's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727299815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In TJX Companies 15 Years Ago Would Be Worth Today

GOVX

GeoVax Labs May Offer & Sell Shares Of Common Stock With Offering Price Of Upto $4.4M From Time To Time Through Or To A.G.P.

Several chip stocks are moving higher after the market close on Wednesday alongside Micron Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), which jumped after the company reported <a href="https://www.benzinga.com/news/earnings/24/09/41034733/micron-q4-earnings-revenue-eps-beat-on-robust-ai-demand-company-sees-significantly-improved-profita">strong quarterly results</a>.
What Happened With MU: Micron beat analyst estimates on the top and bottom lines, reporting revenue of $7.75 billion versus <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $7.635 billion, and earnings of $1.18 per share versus estimates of $1.13 per share.
Micron said its 93% revenue growth in the quarter was driven by robust <a href="http://benzinga.com/topic/ai">AI</a> demand, which was the main driver of chip stock appreciation in recent years.
The memory-chip giant also guided for &#8220;significantly improved profitability&#8221; in fiscal 2025, which appears to be sparking the surge in shares. Micron stock was up 13.2% at $108.37 at the time of writing, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Don&#8217;t Miss: <a href="https://www.benzinga.com/news/earnings/24/09/41034733/micron-q4-earnings-revenue-eps-beat-on-robust-ai-demand-company-sees-significantly-improved-profita">Micron Q4 Earnings: Revenue, EPS Beat On &#8216;Robust AI Demand,&#8217; Company Sees &#8216;Significantly Improved&#8217; Profitability Ahead, Shares Surge</a>
Why It Matters: Micron focuses on making memory chips. Other big players in the semiconductor memory market like Western Digital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) and Lam Research Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) are seeing the biggest gains after the bell, with both up more than 4% in after-hours trading at the time of writing, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Other chipmakers making moves after the bell include NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>), Taiwan Semiconductor Manufacturing Company Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) and Arm Holdings Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>). Several chip stocks were up roughly 1% after hours at last check.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/41033617/voo-vs-vti-vanguards-s-p-500-total-stock-market-etfs-hit-new-highs-as-s-p-500-reaches-record-level">VOO Vs. VTI: Vanguard&#8217;s S&amp;P 500, Total Stock Market ETFs Hit New Highs As S&amp;P 500 Reaches Record Level</a></li>
</ul>
Photo: Courtesy of Arm Holdings.

Tech

LRCX

MRVL

NVDA

Western Digital, Nvidia, Other Chip Stocks Are Rising Wednesday: What's Behind The Move?

Macro Economic Events

Economics

Federal Reserve

Fed's Kugler Says Fed Funds Rate Determines Policy; Balance Sheet Shrinking Is Not A Key Part Of Achieving Mandates; We Are Not Celebrating, We Are Not There Yet, On 2% Inflation Goal

Free Cash Flow before Growth (FCFbG) guidance increased to $1,975 million - $2,125 million from $1,825 - $2,075 million, representing a midpoint increase of $100 million.

Guidance

NRG Energy Lifts FY24 Adjusted EBITDA Guidance From $3.30B - $3.55B To $3.525B - $3.675B

A leading player in psychoactive hemp-derived products (PHDs), LFTD Partners Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LIFD#OTC">LIFD</a>) is trading at just 0.2x CY24 EV/Sales, offering a steep discount. The stock has plummeted over 90% from its April 2021 peak but remains cash flow positive with a net cash position, leaving the company ripe for expansion through mergers and acquisitions. 
Despite regulatory pressures, LIFD's compliant strategy is expected to drive market share gains. According to a report from Zuanic &amp; Associates, the stock could see a 5x rise by December 2025.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Valuation And Growth Potential</h3>
LIFD trades at 0.2x CY24 EV/Sales, below its estimated liquidation value. <a href="https://www.benzinga.com/topic/pablo-zuanic">Zuanic&#8217;s report </a>suggests that if LIFD were to reach 0.5x sales on projected estimates, the stock could rise 5x by December 2025.&nbsp;
This makes the stock an attractive, albeit speculative, investment. The analyst assigns only a 10% probability to a scenario of a federal ban on PHDs, providing further support for the stock's upside potential. However, the future of LIFD is highly binary, driven by regulatory developments.
<h3 class="wp-block-heading">Regulatory Risks And Opportunities</h3>
LIFD's business has been heavily impacted by regulatory challenges at both the state and federal levels, with 19 states having banned <a href="https://www.benzinga.com/topic/hemp">PHDs</a> outright.&nbsp;
However, according to Zuanic, the upcoming<a href="https://www.benzinga.com/markets/cannabis/24/05/39006814/house-committee-approval-of-amendment-eliminating-90-of-hemp-dervied-products-could-drive-wedge-"> Farm Bill</a> is expected to delegate the regulation of PHDs to individual states, potentially allowing LIFD to capitalize on compliant strategies in states with strict regulations rather than outright bans.&nbsp;
This could lead to market share gains and top-line growth.
Zuanic notes that LIFD has the opportunity to benefit from collaboration with THC cannabis companies entering the PHD space, which could validate the compliant PHD market and lead to potential joint lobbying efforts.&nbsp;
The long-term regulatory convergence between PHDs and THC products is another potential upside.
Read Also:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/09/40906131/this-is-life-or-death-families-of-disabled-children-panic-over-gov-newsoms-hemp-cbd-ban-and-eval">&#8216;This Is Life Or Death&#8217;: Families Of Disabled Children Panic Over Gov. Newsom&#8217;s Hemp CBD Ban And Evaluate Lawsuit</a>
<h3 class="wp-block-heading">Bull Vs. Bear Case</h3>
In the bull case, if the regulatory landscape clarifies and no state bans emerge in key markets, LIFD's EV/Sales multiple could return to a 0.5-1.0x range.&nbsp;
This would imply a substantial upside. In the bear case, if federal legislation leads to a ban on PHDs or the company's nutraceutical strategy fails, the stock could face a total loss in value. However, Zuanic assigns just a 10% probability to this worst-case scenario.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">Gov. Newsom&#8217;s Hemp Ban Goes Into Effect: Consequences For Industry, Investors, Patients</a>

Initiation

Analyst Ratings

LIFD's 5x Potential: Is This Psychoactive Hemp Stock The Next Big Speculative Buy?

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

RenovaCare

RenovaCare (RCAR) Forecast

RenovaCare (OTC:RCAR) Stock, Quote.Headers.trade-ideas